March 24 (Reuters) - A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk’s haemophilia B drug.
The Committee for Medicinal Products for Human Use gave a positive opinion on the drug, Refixia, intended for the treatment and prevention of bleeding in patients 12 years and above with haemophilia B. bit.ly/2n1edgs
Haemophilia B is caused by the deficiency of the factor IX gene that is instrumental in blood clotting.
The panel’s opinion will now be reviewed by the EMA. (Reporting by Rahul B in Bengaluru; Editing by Anil D‘Silva)